688221 前沿生物
已收盘 04-30 15:00:02
资讯
新帖
简况
从“抗艾第一股”到小核酸新贵 前沿生物股价与业绩齐飞 靠GSK千万美元授权金逆势涨停
时代财经 · 04-27
从“抗艾第一股”到小核酸新贵 前沿生物股价与业绩齐飞 靠GSK千万美元授权金逆势涨停
前沿生物（688221）发布2026年第一季度报告，4月27日股价上涨20.0%
证券之星 · 04-27
前沿生物（688221）发布2026年第一季度报告，4月27日股价上涨20.0%
龙虎榜 | 沪股通、杭州帮扫货前沿生物，温州帮兑现合力泰1.3亿元
格隆汇 · 04-27
龙虎榜 | 沪股通、杭州帮扫货前沿生物，温州帮兑现合力泰1.3亿元
4月27日前沿生物涨20.00%，易方达医疗保健行业混合A基金重仓该股
证券之星 · 04-27
4月27日前沿生物涨20.00%，易方达医疗保健行业混合A基金重仓该股
前沿生物涨20.00%，开源证券二个月前给出“买入”评级
证券之星 · 04-27
前沿生物涨20.00%，开源证券二个月前给出“买入”评级
4月27日前沿生物（688221）涨停分析：GSK合作、业绩扭亏、研发突破驱动
证券之星 · 04-27
4月27日前沿生物（688221）涨停分析：GSK合作、业绩扭亏、研发突破驱动
前沿生物（688221）2026年一季报简析：营收净利润同比双双增长，存货明显上升
证券之星 · 04-26
前沿生物（688221）2026年一季报简析：营收净利润同比双双增长，存货明显上升
每周股票复盘：前沿生物（688221）Q1营收增948.89%，股东户数增24.16%
证券之星 · 04-26
每周股票复盘：前沿生物（688221）Q1营收增948.89%，股东户数增24.16%
图解前沿生物年报：第四季度单季净利润同比下降1265.89%
证券之星 · 04-25
图解前沿生物年报：第四季度单季净利润同比下降1265.89%
4月24日前沿生物发布公告，股东减持1万股
证券之星 · 04-24
4月24日前沿生物发布公告，股东减持1万股
前沿生物（688221）披露关于开展外汇衍生品交易业务的公告，4月3日股价下跌2.62%
证券之星 · 04-03
前沿生物（688221）披露关于开展外汇衍生品交易业务的公告，4月3日股价下跌2.62%
每周股票复盘：前沿生物（688221）收GSK 4000万美元首付款
证券之星 · 03-22
每周股票复盘：前沿生物（688221）收GSK 4000万美元首付款
前沿生物（688221）披露收到葛兰素史克授权许可协议首付款公告，3月18日股价上涨2.26%
证券之星 · 03-18
前沿生物（688221）披露收到葛兰素史克授权许可协议首付款公告，3月18日股价上涨2.26%
4000万美元首付款到账：前沿生物与GSK授权合作协议持续推进中
财中社 · 03-18
4000万美元首付款到账：前沿生物与GSK授权合作协议持续推进中
前沿生物(688221.SH)：FB7013注射液获得药物临床试验批准
智通财经 · 03-18
前沿生物(688221.SH)：FB7013注射液获得药物临床试验批准
前沿生物跌4.7% A股募20亿IPO瑞银证券保荐
中金财经 · 03-12
前沿生物跌4.7% A股募20亿IPO瑞银证券保荐
每周股票复盘：前沿生物（688221）2025年亏损2.617亿元
证券之星 · 03-01
每周股票复盘：前沿生物（688221）2025年亏损2.617亿元
前沿生物发布2025年度业绩快报，亏损2.617亿元
证券之星 · 02-27
前沿生物发布2025年度业绩快报，亏损2.617亿元
牵手葛兰素史克，前沿生物扭亏寻到“良药”？
新京报 · 02-25
牵手葛兰素史克，前沿生物扭亏寻到“良药”？
前沿生物：2027年计划推动1-2款小核酸产品完成IND申报
证券日报 · 02-25
前沿生物：2027年计划推动1-2款小核酸产品完成IND申报
加载更多
公司概况
公司名称：
前沿生物药业(南京)股份有限公司
所属行业：
医药制造业
上市日期：
2020-10-28
主营业务：
前沿生物药业(南京)股份有限公司的主营业务是抗病毒和肌肉骨骼疼痛治疗药物的研发、生产和销售业务。公司的主要产品是艾可宁。
发行价格：
20.50
{"stockData":{"symbol":"688221","market":"SH","secType":"STK","nameCN":"前沿生物","latestPrice":20.93,"timestamp":1777532402000,"preClose":21.1,"halted":0,"volume":27503892,"delay":0,"changeRate":-0.0081,"floatShares":375000000,"shares":375000000,"eps":0.0093,"marketStatus":"已收盘","change":-0.17,"latestTime":"04-30 15:00:02","open":21.06,"high":21.84,"low":20.67,"amount":582000000,"amplitude":0.0555,"askPrice":20.93,"askSize":466,"bidPrice":20.92,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.0093,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.1,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":23.21,"lowLimit":18.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":374578653,"isCdr":false,"pbRate":7.07,"roa":"--","peRate":2250.537634,"roe":"22.91%","epsLYR":-0.72,"committee":-0.315734,"marketValue":7840000000,"turnoverRate":0.0734,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-06。","afterMarket":{"amount":192807.16,"volume":9212,"close":20.93,"buyVolume":1375,"sellVolume":0,"time":1777534437559,"indexStatus":"已收盘 04-30 15:30:00","preClose":21.1},"floatMarketCap":7840000000},"requestUrl":"/m/hq/s/688221","defaultTab":"news","newsList":[{"id":"2630393046","title":"从“抗艾第一股”到小核酸新贵 前沿生物股价与业绩齐飞 靠GSK千万美元授权金逆势涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393046","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630393046?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:46","pubTimestamp":1777286760,"startTime":"0","endTime":"0","summary":"4月27日，在医药股普遍承压、板块整体走弱的背景下，创新药企前沿生物（688221.SH）却逆势爆发，开盘后快速拉升触及20%的涨停板，截至收盘，前沿生物涨停封板，报22.74元/股。前沿生物成立于2003年，创始人谢东出生于1966年，曾领导和参与了多个艾滋病新药的全球开发与上市工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720433081.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","GSKH","GSK","BK4007","BK4532","BK0239","GSK.UK","BK4585","688221","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364390","title":"前沿生物（688221）发布2026年第一季度报告，4月27日股价上涨20.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364390?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:37","pubTimestamp":1777282642,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，前沿生物报收于22.74元，较前一交易日上涨20.0%，最新总市值为85.18亿元。该股当日开盘22.0元，最高22.74元，最低21.69元，成交额达16.03亿元，换手率为18.92%。近日，前沿生物药业（南京）股份有限公司发布《2026年第一季度报告》。研发投入合计为23,613,376.00元，占营业收入比例为7.95%。本报告期末总资产为1,850,450,931.42元，上年度末为1,578,310,514.11元；归属于上市公司股东的所有者权益为1,108,277,874.52元，上年度末为876,868,792.00元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700032738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630612903","title":"龙虎榜 | 沪股通、杭州帮扫货前沿生物，温州帮兑现合力泰1.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630612903","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630612903?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:33","pubTimestamp":1777282398,"startTime":"0","endTime":"0","summary":"单日净买入额前三为江海股份、华电辽能、良信股份","market":"us","thumbnail":"https://img3.gelonghui.com/03f3a-1f7e258f-7978-4cbc-888d-0488dd2c4b27.jpg?guru_height=3465&guru_width=5145&guru_size=1391695","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/03f3a-1f7e258f-7978-4cbc-888d-0488dd2c4b27.jpg?guru_height=3465&guru_width=5145&guru_size=1391695"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4564933","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0132","BK0196","BK0070","BK0153","000159.SH","BK0077","BK0214","688221","BK0171","BK0239","002217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336659","title":"4月27日前沿生物涨20.00%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336659","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630336659?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:29","pubTimestamp":1777278541,"startTime":"0","endTime":"0","summary":"证券之星消息，4月27日前沿生物涨20.00%，收盘报22.74元，换手率18.92%，成交量70.88万手，成交额16.03亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共10家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为32.51亿元，最新净值3.964，较上一交易日上涨0.56%，近一年上涨13.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630652033","title":"前沿生物涨20.00%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2630652033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630652033?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:28","pubTimestamp":1777278532,"startTime":"0","endTime":"0","summary":"今日前沿生物（688221）涨20.00%，收盘报22.74元。2026年2月24日，开源证券研究员余汝意,巢舒然发布了对前沿生物的研报《公司信息更新报告：两款siRNA管线独家授权GSK，携手推进全球合作》，该研报对前沿生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为75.73%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为兴业证券的杨希成、黄翰漾、孙媛媛。前沿生物（688221）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630665363","title":"4月27日前沿生物（688221）涨停分析：GSK合作、业绩扭亏、研发突破驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2630665363","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630665363?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:39","pubTimestamp":1777275547,"startTime":"0","endTime":"0","summary":"证券之星消息，前沿生物4月27日涨停收盘，收盘价22.74元。今日前沿生物涨停的可能因素有：与GSK达成小核酸管线授权合作，获5300万美元首付款及最高9.5亿美元里程碑收益；2026年一季度归母净利润2.27亿元，同比大增615.38%，实现扭亏为盈；核心siRNA药物FB7013获批临床，多个项目推进至IND阶段；艾可宁销售持续增长，医保覆盖与基层拓展成效显著。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700022938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630807174","title":"前沿生物（688221）2026年一季报简析：营收净利润同比双双增长，存货明显上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2630807174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630807174?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:17","pubTimestamp":1777155429,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期前沿生物发布2026年一季报。截至本报告期末，公司营业总收入2.97亿元，同比上升948.89%，归母净利润2.27亿元，同比上升615.38%。本报告期前沿生物存货明显上升，存货同比增幅达72.26%。本次财报公布的各项数据指标表现尚佳。持有前沿生物最多的基金为易方达医疗保健行业混合A，目前规模为32.51亿元，最新净值3.964，较上一交易日上涨0.56%，近一年上涨13.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003183.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804922","title":"每周股票复盘：前沿生物（688221）Q1营收增948.89%，股东户数增24.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804922?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:53","pubTimestamp":1777146788,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，前沿生物报收于18.95元，较上周的19.65元下跌3.56%。本周关注点来自业绩披露要点：2026年一季度主营收入2.97亿元，同比上升948.89%。股东户数变动截至2026年3月31日，公司股东户数为1.62万户，较2025年12月31日增加3156.0户，增幅24.16%。户均持股数量由2.87万股降至2.31万股，户均持股市值为43.77万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630291718","title":"图解前沿生物年报：第四季度单季净利润同比下降1265.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630291718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630291718?lang=zh_cn&edition=full","pubTime":"2026-04-25 01:13","pubTimestamp":1777050814,"startTime":"0","endTime":"0","summary":"证券之星消息，前沿生物2025年年报显示，当年度公司主营收入1.23亿元，同比下降4.7%；归母净利润-2.68亿元，同比下降33.11%；扣非净利润-3.02亿元，同比上升7.64%；其中2025年第四季度，公司单季度主营收入2001.27万元，同比下降47.1%；单季度归母净利润-1.08亿元，同比下降1265.89%；单季度扣非净利润-1.17亿元，同比下降24.12%；负债率44.44%，投资收益-106.3万元，财务费用-9.12万元，毛利率33.22%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500003664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629846260","title":"4月24日前沿生物发布公告，股东减持1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629846260","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629846260?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:01","pubTimestamp":1777032102,"startTime":"0","endTime":"0","summary":"证券之星消息，4月24日前沿生物发布公告《前沿生物:前沿生物简式权益变动报告书》，其股东何春华于2025年10月24日至2026年4月24日间合计减持1.0万股，占公司目前总股本的0.0027%，变动期间该股股价上涨33.92%，截止4月24日收盘报18.95元。股东增减持详情见下表：根据前沿生物2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400060815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624665604","title":"前沿生物（688221）披露关于开展外汇衍生品交易业务的公告，4月3日股价下跌2.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624665604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624665604?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:22","pubTimestamp":1775208160,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，前沿生物报收于20.41元，较前一交易日下跌2.62%，最新总市值为76.45亿元。该股当日开盘20.64元，最高20.96元，最低19.75元，成交额达3.92亿元，换手率为5.16%。该事项无需提交股东大会审议。公司强调交易以套期保值为目的，不进行投机，但仍存在市场、流动性、履约等风险。公司将遵循相关制度，加强风险管控。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621965127","title":"每周股票复盘：前沿生物（688221）收GSK 4000万美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2621965127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621965127?lang=zh_cn&edition=full","pubTime":"2026-03-22 01:50","pubTimestamp":1774115424,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，前沿生物报收于18.28元，较上周的19.0元下跌3.79%。公司公告汇总：FB7013注射液获临床试验批准，拟用于原发性IgA肾病治疗。截至2026年3月19日，公司已收到GSK支付的4,000万美元首付款。该产品已于2025年12月31日获受理，符合药品注册相关要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620239802","title":"前沿生物（688221）披露收到葛兰素史克授权许可协议首付款公告，3月18日股价上涨2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620239802","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620239802?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:18","pubTimestamp":1773825520,"startTime":"0","endTime":"0","summary":"截至2026年3月18日收盘，前沿生物报收于19.91元，较前一交易日上涨2.26%，最新总市值为74.58亿元。近日，前沿生物药业（南京）股份有限公司披露《自愿披露关于收到与葛兰素史克签署的授权许可协议首付款的公告》。公告显示，2026年2月16日，公司与葛兰素史克签署独家授权许可协议，GSK获得公司两款小核酸管线产品在全球范围内的独家开发、生产及商业化权利。截至2026年3月19日，公司已收到GSK支付的4,000万美元首付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800029729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620235848","title":"4000万美元首付款到账：前沿生物与GSK授权合作协议持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2620235848","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620235848?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:15","pubTimestamp":1773821756,"startTime":"0","endTime":"0","summary":"3月18日，前沿生物（688221）发布公告，截至本公告披露日，公司已收到由葛兰素史克（GSK.N）按协议约定支付的4000万美元首付款。据悉，2026年2月16日，公司与葛兰素史克签署独家授权许可协议，葛兰素史克将获得两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。2025年前三季度，前沿生物实现收入1.03亿元，归母净利润-1.60亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675959935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","LU1829250122.USD","BK4588","GSK.UK","GSKH","688221","BK0239","BK4532","BK4585","GSK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620233417","title":"前沿生物(688221.SH)：FB7013注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2620233417","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620233417?lang=zh_cn&edition=full","pubTime":"2026-03-18 16:13","pubTimestamp":1773821588,"startTime":"0","endTime":"0","summary":"智通财经APP讯，前沿生物(688221.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司FB7013注射液拟用于原发性IgA肾病的治疗开展临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"前沿生物(688221.SH)：FB7013注射液获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618184581","title":"前沿生物跌4.7% A股募20亿IPO瑞银证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2618184581","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618184581?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:33","pubTimestamp":1773304392,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 前沿生物 今日收报18.86元，跌幅4.70%，总市值70.65亿元。该股目前处于破发状态。 前沿生物于2020年10月28日在上交所科创板上市，本次发行股份数量为8,996万股，发行价格为20.50元/股，保荐机构为瑞银证券有限责任公司，保荐代表人为崔健民、严鹏举，联席主承销商为中信证券股份有限公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32063316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","159982","399300","161027","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843332","title":"每周股票复盘：前沿生物（688221）2025年亏损2.617亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843332","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843332?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:49","pubTimestamp":1772300950,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，前沿生物报收于21.2元，较上周的22.6元下跌6.19%。来自公司公告汇总：公司与葛兰素史克签署授权许可协议，获4,000万美元首付款。业绩披露要点前沿生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损2.617亿元，同比减少29.96%。公司负责早期开发工作，葛兰素史克负责后续全球临床开发、注册申报及商业化。主要因2024年处置子公司股权产生投资收益，2025年无此类收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614764833","title":"前沿生物发布2025年度业绩快报，亏损2.617亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614764833","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614764833?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:13","pubTimestamp":1772183610,"startTime":"0","endTime":"0","summary":"证券之星消息，前沿生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损2.617亿元，同比减少29.96%。前沿生物（688221）主营业务：抗病毒和肌肉骨骼疼痛治疗药物的研发、生产和销售业务。该股最近90天内共有2家机构给出评级，买入评级2家。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700028107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688221","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614994087","title":"牵手葛兰素史克，前沿生物扭亏寻到“良药”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614994087","media":"新京报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614994087?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:08","pubTimestamp":1772024880,"startTime":"0","endTime":"0","summary":"一桩BD（商务拓展）交易的官宣，前沿生物股价便上演了“过山车”行情。2月25日，前沿生物股价收跌4.09%，而开年首个交易日，公司股价大涨，收盘报24.7元/股，涨幅达9.29%。在此之前，公司宣 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260225/c674915502.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260225/c674915502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688221"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614806320","title":"前沿生物：2027年计划推动1-2款小核酸产品完成IND申报","url":"https://stock-news.laohu8.com/highlight/detail?id=2614806320","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614806320?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:05","pubTimestamp":1772024700,"startTime":"0","endTime":"0","summary":"一是高端仿制药领域，两款分别面向美国、中国市场的产品，计划于未来两年内获批上市，为公司带来现金流支撑；二是HIV领域，持续推进差异化产品研发，力争推出1款新的创新药品种；三是小核酸领域，核心推进已公开的FB7013、FB7011、FB7023、FB7033四款管线，积极争取推动FB7023/FB7033中的一款完成IND申报，同时计划推进一款肝外递送相关早期产品达到PCC阶段；2027年计划推动1-2款小核酸产品完成IND申报，更多肝外递送早期产品达到PCC阶段。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-25/doc-inhnzvzk2138518.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-25/doc-inhnzvzk2138518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","IND","688221"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777661802591,"stockEarnings":[{"period":"1week","weight":0.1022},{"period":"1month","weight":0.1045},{"period":"3month","weight":-0.1422},{"period":"6month","weight":0.313},{"period":"1year","weight":1.4394},{"period":"ytd","weight":0.1596}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"前沿生物药业(南京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16219人(较上一季度增加24.16%)","perCapita":"23095股","listingDate":"2020-10-28","address":"江苏省南京市江宁区至道路8号","registeredCapital":"37457万元","survey":" 前沿生物药业(南京)股份有限公司的主营业务是抗病毒和肌肉骨骼疼痛治疗药物的研发、生产和销售业务。公司的主要产品是艾可宁。","listedPrice":20.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"前沿生物(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供前沿生物(688221)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"前沿生物,688221,前沿生物股票,前沿生物股票老虎,前沿生物股票老虎国际,前沿生物行情,前沿生物股票行情,前沿生物股价,前沿生物股市,前沿生物股票价格,前沿生物股票交易,前沿生物股票购买,前沿生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"前沿生物(688221)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供前沿生物(688221)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}